Articles On Micro-X (ASX:MX1)

ASX healthcare under pressure but producing world-class science and commercial opportunities Morgans sees value emerging in the sector, with positive catalysts moving share prices HealthInvest to showcase five emerging ASX-listed healthcar...

ASX rebounds 1.17% after Trump pauses planned Iran strikes Woolies and Coles lead staples surge as battered defensives bounce back Lithium and healthcare big guns rally as oil prices cool (okay, slightly)   The United States is observing...

Highlights Invion shares surged after announcing a new wet AMD collaboration with South Korea’s Sangmyung. The partnership aims to explore a photodynamic therapy approach for difficult eye diseases. Broader biotech activity also inclu...

  Micro-X US subsidiary secures a $1.3 million contract extension from the U.S. Department of Homeland Security Extension supports continued testing and algorithm development for the Passenger Self-Screening Checkpoint program through to...

Invion shares surge 40% on the back of an early stage wet aged-related macular degeneration collab Amplia launches a new pancreatic cancer study, while Island tackles Marburg Micro-X lands US airport security screening extension   Cancer...

ASX health sector fell 3.01% for the week, while broader market rose 0.22% Morgans healthcare team has updated research on several stocks following latest reporting season  Owner of Chemist Warehouse chain, Sigma Healthcare, posted strong...

Micro-X posts March quarter results highlighting key progress across clinical, commercial and security programs The first Head CT test bench at the Royal Melbourne Hospital installed and commissioned Engineering work continues on ambulance...

Sleep apnoea giant Resmed splurges $US360 million ($500m) to buy a company tackling restless leg syndrome April was the cruellest month for ASX biotechs Arovella coup claims more scalps   Having conquered sleep apnoea (snoring), ResMed (...

Ageing is quietly becoming a massive healthcare opportunity From stroke to lungs to memory, the cracks are showing LTR Pharma taps into the part no one talks about   Australians are getting older, but this isn’t a generation easing into q...

ASX slides 0.39% with 8 of 11 sectors lower Oil rebounds to +US$100 a barrel as US blockades Strait of Hormuz Energy, utilities, telecoms sectors outperform The fragile two-week ceasefire surrounding the Iranian conflict is in dire jeopar...

Even in developed countries, large swathes of the population live in rural and remote areas, far away from gold standard healthcare ASX healthcare providers are seeking to fill the gap with innovative devices EMvision’s Emu and First Resp...

ASX health sector falls about 2.5% for the past five days while broader market is just scraping by as the Middle East conflict takes a toll Immutep plunges 90% on Friday after abandoning its Phase III trial of lung cancer treatment  Pro Me...

Nasdaq tech rally hits its first real wobble AI hype fades as investors ask where the profits are ASX tech slides 9pc in February, matching January slump   For the last two years, Wall Street has basically been riding on one engine: big t...

ASX closes down 1.94%, wiping $63 billion off the Australian sharemarket in a single session Global markets plunge as fallout following fallout from Iran, US and Israel conflict  All 11 ASX sectors finish lower with materials down ~3% as c...

Micro-X lifts half year revenue 155% to a record $10.1 million in H1 FY26 Ends H1 with cash and cash equivalents of $4.9 million Progress on major programs with improved commercial traction   Special Report: Micro-X has posted record hal...

ASX healthcare sector falls 13.31% in February as benchmark ASX 200 up 4% Blood products and vaccines giant CSL weighed heavily on sector down 19.1% in February Rhythm Biosciences up 48% in February to be sector’s biggest gainer for the mo...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin FNArena's Monitor keeps track of corporate earnings result releases, including broke...

The ASX closed 0.5% lower on Friday but at least it remained up for the week Energy best performing sector on ASX today as oil price rises on Middle East tensions Mixed day of earnings with QBE Insurance and Telix Pharmaceuticals posting s...

Host Tylah Tully sits down with Micro-X (ASX:MX1) CEO Kingsley Hall to discuss the installation of the company’s first head CT test bench at Royal Melbourne Hospital, marking a major milestone as it moves into human clinical trials. Hall ex...

ASX 200 closes 1.66% higher to 9,014.80, setting a new 50-day high CBA rises more than 7% after posting $5.45 billion profit for H1 FY26  Healthcare giant CSL falls 5.75% after its latest half-year results    It was a tale of two heavywei...

Stockhead’s Tylah Tully previews the 2026 ahead for Micro-X (ASX:MX1) and recaps the goals the company achieved throughout 2025. Tune in to hear all the details.   This video was developed in collaboration with Micro-X, a Stockhead adverti...

ASX healthcare sector rises 2.25% in January as benchmark ASX 200 up 1.78% Index largely supported by the sector’s largest stock CSL, up 5.1% in January Anteris and PYC announce monster capital raises with strong support from US investors...

Micro-X starts activation of the first hospital trial site for its portable Head CT scanner designed for stroke patients Human pilot study designed to support future regulatory applications for the Head CT scanner for stroke Additional tes...

ASX health sector up 0.11% for the week, while broader market rises 0.23% Week dominated by quarterly results with several companies reaching key milestones  Morgans upgrades Imricor after  US FDA breakthrough clearance for its NorthStar M...

Do you want some exposure to the small side of the market? If you do, then it could be worth listening to what Morgans is saying about the two small-cap ASX shares named below. Here's why the broker thinks they could be buys for investors w...

With the sun setting on another ‘issues rich’ year for ASX biotechs, Dr Boreham applies his stethoscope to the soaring highlights and cratering lowlights.   As usual we adopt the user-friendly A to Z format. If only drug, device and diagnos...

Highlights Micro-X advances its ASX quotation strategy Broader implications for market visibility and liquidity How the move fits within the wider Australian equities landscape Micro-X’s ASX share quotation move highli...

Micro-X raises $6.18 million via a placement at 8.0c per share Security development partner Billion Prima commits $3.0m to lift its stake to 8.6% Funds to support medical imaging commercial activities, manufacturing scale-up and working ca...

ASX200 gives up early gains of +0.49% to finish -0.42% Nine of 11 sectors lower; 113 stocks falling and 81 rising Resources, banks, reverse momentum to drag market lower   Tech and resources weigh heavily Despite a pretty energetic start...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX gains 23 points or 0.27% in choppy session of trade Real estate plunges 2.11% while banks and resources make strong gains Bond yields climb to highest level in 2025 on rate hike fears   ASX rides commodity wave higher The ASX 200 adde...

Micro-X debuts upgraded Rover mobile X-ray at the Radiological Society of North America annual meeting Enhanced Rover builds on Micro-X’s position in ultra-lightweight, motor-free mobile imaging Company also showcases its expanding pipelin...

Micro-X is adopting a partnership-led strategy to de-risk development of its world-leading cold cathode x-ray technology The company has secured around $80 million in funding in recent years to advance products including a portable Head CT...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

ASX tech hits a speed bump in October New winners rise as old giants stumble Archer, Weebit and co keep the spark alive   October wasn’t kind to ASX tech investors. The S&P/ASX All Technology Index (XIJ) fell a hefty 8%, making it the...

Optiscan Imaging led the biotech pack in October, while some of the Big Four stocks were late scratchings Does CSL have an iron deficiency? Weebit Nano ‘mini me’ Dorsavi quietly jockeys for position in the high-stakes chip race   The ASX...

Host Fraser Palamara speaks with Professor Steven Davis from the Australian Stroke Alliance about the massive global impact of stroke and the technology reshaping how it’s treated. Stroke is the second leading cause of death worldwide, affe...

ASX health sector moved up 1.30% for the week, while broader market inched up 0.12% This week: PainChek’s groundbreaking digital app scored coveted FDA De Novo clearance; The FDA lifted a clinical hold on Neurizon’s lead drug candidate for...

If you have a high tolerance for risk, then it can be worth having a few small cap ASX shares in a balanced portfolio. But which ones could be buys? Fortunately, the team at Morgans has done the hard work for you by picking out two small ca...

ASX holds firm as oil spills, gold dips and tech sector surges Cannon-Brookes stirs up AGL climate clash DigiCo Eagers and Mesoblast fly high   By the close of Friday, the ASX’s 0.46% gain looked pretty darn respectable considering oil’s...

Highlights Tech and healthcare lead early ASX trading momentum Small caps dominate headlines with strong project updates Energy and resources remain under pressure amid commodity shifts Tech and healthcare stocks lifte...

Highlights: Key ASX-listed companies report milestone updates Healthcare, infrastructure, defence and consumer segments advance Market resilience holds despite global uncertainty ASX market strengthened this week as Di...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully unpacks the latest news from Micro-X (ASX:MX1), who have received a $3.3 million dollar order from the Malaysian Governm...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

Mag 7 drive Wall Street’s best September in years
 ASX tech takes a beating while DroneShield soars
 I Synergy strikes Octagram deal to chase Web3 frontier   Mag 7 carries the load in September September has historically been the weakest...

ASX 200 down just 3 points, All Ords up 0.7 points Defensive stocks bulwark ASX against US government shut down China-BHP stoush and lithium losses weigh on materials sector ASX plays it safe as US government shutdown kicks off The ASX 2...

First of three Micro-X Head CT test benches completed and ready for installation at an Australian hospital to begin stroke imaging trials Pivotal study to run over six to nine months comparing Head CT images with conventional CT scans of s...

Highlights Hot inflation dampens expectations for easing monetary policy Banks, resources, and tech stocks weighed on the broader ASX stock market Select mining and energy players delivered upbeat exploration and project upd...

Current cancer imaging tools are “not good enough”, Imagion chief Bob Proulx says Micro-x announces second grant in the space of two days Race Oncology wins Korean trial assent … in South Korea, of course   Imagion Biosystems (ASX:IBX) sa...

Micro-X awarded $4.4 million Australian government grant to build and trial an ambulance with its Head CT device to detect stroke Company plans a full patient imaging trial to collect data from stroke patients transported in the stroke amb...